Antabio CEO Says M&A Is His ‘Exit Strategy’
‘Broken’ AMR Model Leaves Antibiotics Maker No Other Choice
Antibiotics specialist Antabio aims to get enough funding to advance its pipeline far enough to become a takeover target.
You may also be interested in...
2020 could be a watershed year in tackling AMR, but success needs market reforms that ensure new antibiotics get to market and prevent innovators going bust, experts tell Scrip.
The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.
AstraZeneca has vowed to slash its carbon emissions to zero by 2025 and ensure its entire value chain is carbon negative by 2030. It will spend up to $1bn to do so.